Brokerages expect Eli Lilly and Company (NYSE:LLY – Get Rating) to report earnings of $1.90 per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Eli Lilly and’s earnings. The lowest EPS estimate is $1.80 and the highest is $2.12. Eli Lilly and reported earnings of $1.87 per share during the same quarter last year, which would indicate a positive year over year growth rate of 1.6%. The company is scheduled to report its next earnings results on Monday, January 1st.
On average, analysts expect that Eli Lilly and will report full-year earnings of $8.34 per share for the current fiscal year, with EPS estimates ranging from $8.15 to $8.80. For the next year, analysts forecast that the company will post earnings of $9.58 per share, with EPS estimates ranging from $9.00 to $9.86. Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for Eli Lilly and.
Eli Lilly and (NYSE:LLY – Get Rating) last released its quarterly earnings results on Thursday, April 28th. The company reported $2.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.32 by $0.30. The firm had revenue of $7.81 billion for the quarter, compared to the consensus estimate of $7.29 billion. Eli Lilly and had a return on equity of 97.58% and a net margin of 20.90%. The company’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter last year, the business posted $1.87 EPS.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction dated Friday, March 4th. The shares were sold at an average price of $262.24, for a total transaction of $55,070,400.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Marschall S. Runge bought 202 shares of the company’s stock in a transaction dated Tuesday, March 1st. The stock was purchased at an average price of $246.78 per share, with a total value of $49,849.56. The disclosure for this purchase can be found here. Insiders have sold 1,327,818 shares of company stock worth $380,782,218 over the last ninety days. Insiders own 0.12% of the company’s stock.
A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in Eli Lilly and by 1.8% in the first quarter. Vanguard Group Inc. now owns 70,481,178 shares of the company’s stock valued at $20,183,695,000 after buying an additional 1,219,424 shares in the last quarter. State Street Corp lifted its holdings in shares of Eli Lilly and by 2.5% in the fourth quarter. State Street Corp now owns 33,929,864 shares of the company’s stock worth $9,372,107,000 after acquiring an additional 813,983 shares during the last quarter. Capital World Investors boosted its stake in shares of Eli Lilly and by 17.0% in the 1st quarter. Capital World Investors now owns 22,358,444 shares of the company’s stock valued at $6,402,838,000 after purchasing an additional 3,242,548 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Eli Lilly and by 2.9% during the 4th quarter. Geode Capital Management LLC now owns 14,731,168 shares of the company’s stock valued at $4,059,130,000 after purchasing an additional 409,009 shares during the last quarter. Finally, Capital International Investors increased its position in Eli Lilly and by 30.5% during the 1st quarter. Capital International Investors now owns 8,839,241 shares of the company’s stock worth $2,532,024,000 after purchasing an additional 2,063,557 shares in the last quarter. 82.75% of the stock is currently owned by institutional investors and hedge funds.
NYSE LLY opened at $323.48 on Friday. Eli Lilly and has a 52 week low of $196.68 and a 52 week high of $324.08. The company has a debt-to-equity ratio of 1.60, a quick ratio of 0.98 and a current ratio of 1.27. The stock’s 50 day moving average price is $295.16 and its two-hundred day moving average price is $269.47. The stock has a market capitalization of $307.36 billion, a price-to-earnings ratio of 47.92, a PEG ratio of 2.27 and a beta of 0.40.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 10th. Shareholders of record on Monday, May 16th will be issued a $0.98 dividend. This represents a $3.92 dividend on an annualized basis and a yield of 1.21%. The ex-dividend date of this dividend is Friday, May 13th. Eli Lilly and’s dividend payout ratio is currently 58.07%.
About Eli Lilly and (Get Rating)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
Read More
- Get a free copy of the StockNews.com research report on Eli Lilly and (LLY)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
Get a free copy of the Zacks research report on Eli Lilly and (LLY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.
